Court To Hear Arguments In High-Stakes Suit Over Zyprexa

Law360, New York (January 23, 2004, 12:00 AM EST) -- A federal court in Indiana will hear arguments Monday in the high-stakes battle for Eli Lilly’s top-selling drug, the $4.3-billion-a-year schizophrenia medicine Zyprexa.

The case is highly unusual because the generics makers are attacking the validity of the research that led to the issuance of the drug’s underlying patent in 1993 by the U.S. Patent and Trademark Office. The patent gives Lilly exclusive right to sell Zyprexa in the U.S. until 2011.

Eli Lilly has sued three generics makers in the U.S. District Court for the...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.